Enterprise Value

234.7M

Cash

47.75M

Avg Qtr Burn

-10.93M

Short % of Float

1.92%

Insider Ownership

3.46%

Institutional Own.

31.63%

Qtr Updated

03/31/23


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
Avasopasem Manganese (GC4419) Details
Head and neck cancer, Cancer

Big Mover™

Susp. Mover™

PDUFA

Approval decision

Rucosopasem Details
Pancreatic cancer, Cancer

Phase 2b

Data readout

Rucosopasem Details
Cancer, Non-small cell lung carcinoma

Phase 2

Data readout

Phase 2

Update

Avasopasem Manganese (GC4419) Details
Infectious disease, COVID-19

Failed

Discontinued